ArticleJournal of immunology research2026
Downregulated Plasma-Derived Extracellular Vesicle MicroRNAs as Novel Biomarkers for Enhanced Tuberculosis Diagnosis.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundTuberculosis (TB) remains a leading global cause of infectious disease mortality, while current diagnostic methods face substantial limitations. Extracellular vesicle (EV)-encapsulated microRNAs (miRNAs) demonstrate significant potential as diagnostic biomarkers. This study aimed to evaluate their diagnostic utility for TB by identifying expression disparities between TB patients and healthy controls (HCs) and exploring EV miRNA diagnostic performance.
methodsHCs were healthy individuals excluded from pulmonary infectious diseases, and TB patients were clinically and laboratory-confirmed cases without other concurrent pulmonary infections. Small RNA sequencing analysis was performed on plasma EVs from a discovery cohort (n = 40) to identify differentially expressed (DE) miRNAs. Findings were validated via quantitative real-time PCR (qRT-PCR) in an independent cohort (n = 24). Subsequently, an EV miRNA combinatorial diagnostic model was developed using random forest classifiers in a modeling cohort (n = 58), incorporating feature selection based on importance scores and correlation coefficients. Hyperparameter optimization and model stability verification were performed via grid search with five-fold cross-validation. Diagnostic performance was evaluated through receiver operating characteristic (ROC) analysis. Bioinformatics analysis included target gene prediction using miRNA databases, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses.
resultsSequencing revealed 67 significantly DE EV miRNAs, with 92.5% demonstrating marked downregulation in TB patients. This pattern was confirmed by qRT-PCR validation. Eleven validated miRNAs were used for model construction. Feature selection identified three optimal miRNAs (miR-19b-3p, miR-181b-5p, and miR-98-5p), generating seven combinatorial models. Individual miRNAs exhibited area under the curves (AUCs) > 0.85, while combinations achieved AUCs > 0.89. Notably, the combinatorial signature of miR-19b-3p and miR-181b-5p demonstrated outstanding diagnostic discrimination (AUC = 1.000; sensitivity and specificity both 100%), with a five-fold cross-validated score of 0.964 indicating robust model stability. Bioinformatics analysis revealed that the target genes of these two miRNAs were enriched in immune response pathways, including the Notch signaling pathway and the cyclic adenosine monophosphate (cAMP) signaling pathway.
conclusionThis EV miRNA signature demonstrates remarkable diagnostic accuracy for TB, offering a clinically actionable solution to diagnostic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.